Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Andrew StanglChristopher WilnerPin LiLucas MaahsClara HwangAmanda PillingPublished in: The Prostate (2023)
Inactivating mutations in SPOP are associated with better response to ARSI treatment in mCRPC overall. Additional analysis with a larger cohort is needed to evaluate the association of SPOP status and outcomes with docetaxel. Race-associated clinical outcomes and molecular features were observed, suggesting the benefit of biomarker-directed therapy selection for individualized patient subsets in guiding treatment decisions for mCRPC patients.
Keyphrases
- end stage renal disease
- squamous cell carcinoma
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- metabolic syndrome
- case report
- stem cells
- peripheral blood
- skeletal muscle
- mesenchymal stem cells
- bone marrow
- replacement therapy
- cell therapy
- weight loss
- rectal cancer
- smoking cessation
- patient reported
- data analysis